Mankind Pharma Ltd
Mon 2/02/2026,15:59:27 | NSE : MANKIND
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 2100.00
Previous Close
₹ 2093.90
Volume
333325
Mkt Cap ( Rs. Cr)
₹85194.71
High
₹ 2120.00
Low
₹ 2046.80
52 Week High
₹ 2716.50
52 Week Low
₹ 2059.40
Book Value Per Share
₹ 370.30
Dividend Yield
0.00
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Mankind Pharma Ltd
Your Vote -
Buy
43.80%
Hold
24.82%
Sell
31.39%
43.80%
137 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
2063.80
40
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
40
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Mankind Pharma Ltd' movement.
| Call Price | Open interest | Strike Price | Put Price | Open interest |
|---|
News
Media spotlight triggers stock stock attention, sentiment.
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Credit Rating
-
Mankind Pharma - Credit Rating
-
Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Mankind Pharma has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025
-
Mankind Pharma - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Comp
-
Mankind Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Mankind Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Mankind Pharma - Trading Window
-
Mankind Pharma - General Updates
-
Mankind Pharma - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 20
-
Mankind Pharma - General Updates
-
Mankind Pharma - Intimation Regarding ESG Rating
-
Mankind Pharma - Intimation Regarding ESG Rating
-
Mankind Pharma - General Updates
-
Mankind Pharma - ESOP/ESOS/ESPS
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Allotment
-
Mankind Pharma - General Updates
-
Mankind Pharma - Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
-
Mankind Pharma - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 20
-
Mankind Pharma - General Updates
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Credit Rating
-
Mankind Pharma - Credit Rating
-
Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Mankind Pharma - Copy of Newspaper Publication
-
Mankind Pharma - Outcome of Board Meeting
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Mankind Pharma - Outcome of Board Meeting
-
Mankind Pharma - Investor Presentation
-
Mankind Pharma - Press Release
-
Mankind Pharma - Financial Results For The Quarter And Half Year Ended 30Th September 2025
-
Mankind Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Mankind Pharma Q2 net profit down 27.67% at Rs 458.90 cr
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Mankind Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Mankind Pharma - Board Meeting Outcome for Outcome Of Board Meeting
-
Mankind Pharma - Intimation Regarding ESG Rating
-
Mankind Pharma - General Updates
-
Mankind Pharma
-
Mankind Pharma
-
Mankind Pharma
Key fundamentals
Evaluate the intrinsic value of Mankind Pharma Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 21888.52 | 9623.8091 | 7783.911 | 6756.6684 | 4829.2702 |
| Liabilities | 21888.52 | 9623.8091 | 7783.911 | 6756.6684 | 4829.2702 |
| Equity | 41.26 | 40.0588 | 40.0588 | 40.0588 | 40.0588 |
| Gross Profit | 2562.55 | 2325.1047 | 1697.3814 | 1799.6143 | 1378.2913 |
| Net Profit | 1945.48 | 1823.4096 | 1248.258 | 1335.1306 | 1084.3747 |
| Cash From Operating Activities | 2322.16 | 1982.9732 | 1798.9871 | 812.2873 | 1022.3277 |
| NPM(%) | 20.48 | 19.68 | 15.35 | 18.39 | 19.61 |
| Revenue | 9497.8 | 9264.8093 | 8127.1532 | 7257.0359 | 5529.5985 |
| Expenses | 6935.25 | 6939.7046 | 6429.7718 | 5457.4216 | 4151.3072 |
| ROE(%) | 12.72 | 11.92 | 8.16 | 8.73 | 7.09 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 08 Aug 2025 | 1 | 100 | 0 | 2567.2 |
Peers
Other companies within the same industry or sector that are comparable to Mankind Pharma Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 683.60 | -1.06 | 0.00 | 1194.55 | 301.39 | 0.73 |
| Lotus Eye Hospital and Institute Ltd | 122.09 | -5.00 | 381.53 | 4352.77 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.95 | -1.00 | 0.00 | 27306.37 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 585.80 | 2.86 | 0.00 | 4104.76 | -604.77 | 0.00 |
Company Info
The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.Major events and milestones:2004 -Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others2005 -Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others2007 -Entered the consumer healthcare segment with the launch of `Manforce' brand-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised Rs.720 million from Monet Limited2009 -Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh2010 -Launched `Preganews' brand in the consumer healthcare segment2012 -Setup the first R&D centre at IMT Manesar, Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)-Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh2015 -Incorporated the Subsidiary, Lifestar Pharma LLC in the US-Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore2017 -Set up the manufacturing facility in Sikkim2018 -The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time2019 -Entered the female infertility segment with the launch of `Dydroboon' tablets2020 -Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets2021 -Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others-Entered into oncology segment with the launch of `Pacliall' injection amongst others-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories-The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited. 2023-Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.-Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.-Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.2024-Mankind Pharma Completes Landmark Acquisition of BSV.-Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.-Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.-Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain). 2025-The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited and Jaspack Industries Private Limited with Mankind Pharma Limited
The Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by the Shareholders pursuant to a special resolution dated July 14, 2005 the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.Major events and milestones:2004 -Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar' tablets amongst others2005 -Set up the first manufacturing facility at Paonta Sahib, Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others2007 -Entered the consumer healthcare segment with the launch of `Manforce' brand-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised Rs.720 million from Monet Limited2009 -Set up the manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh2010 -Launched `Preganews' brand in the consumer healthcare segment2012 -Setup the first R&D centre at IMT Manesar, Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)-Set up the manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh2015 -Incorporated the Subsidiary, Lifestar Pharma LLC in the US-Incorporated the Subsidiary, Mankind Pharma Pte. Limited in Singapore2017 -Set up the manufacturing facility in Sikkim2018 -The manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time2019 -Entered the female infertility segment with the launch of `Dydroboon' tablets2020 -Incorporated the Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets2021 -Incorporated the Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others-Entered into oncology segment with the launch of `Pacliall' injection amongst others-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories-The Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited. 2023-Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence.-Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API.-Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution.2024-Mankind Pharma Completes Landmark Acquisition of BSV.-Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab.-Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups.-Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain). 2025-The Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited and Jaspack Industries Private Limited with Mankind Pharma Limited
Read More
Parent Organisation
Mankind Pharma Ltd.
Founded
03/07/1991
Managing Director
Mr.Rajeev Juneja
NSE Symbol
MANKINDEQ
FAQ
The current price of Mankind Pharma Ltd is ₹ 2063.80.
The 52-week high for Mankind Pharma Ltd is ₹ 2120.00 and the 52-week low is ₹ 2046.80.
The market capitalization of Mankind Pharma Ltd is currently ₹ 85194.71. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Mankind Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Mankind Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Mankind Pharma Ltd shares.
The CEO of Mankind Pharma Ltd is Mr.Rajeev Juneja, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.